Strides Pharma Science Reports Significant Q1 Profit Boost

Strides Pharma Science has announced an 81% year-on-year increase in profit after tax, reaching Rs 114 crore for Q1 ending June 30, 2025. The revenue also saw a rise to Rs 1,120 crore. The company attributes its success to effective cost management and plans to enhance its R&D efforts for sustainable growth.

Devdiscourse News Desk | New Delhi | Updated: 29-07-2025 14:57 IST | Created: 29-07-2025 14:57 IST

Strides Pharma Science Reports Significant Q1 Profit Boost — This image is AI-generated and does not depict any real-life event or location. It is a fictional representation created for illustrative purposes only.

Country:
India

Strides Pharma Science has reported a significant surge in its profit after tax, which increased by 81% year-on-year to Rs 114 crore for the first quarter ending June 30, 2025. This growth marks a considerable improvement from the Rs 63 crore recorded in the same period last year.

The company's revenue also rose to Rs 1,120 crore for the June quarter, compared to Rs 1,054 crore the previous year, as stated in a regulatory filing. Badree Komandur, MD & Group CEO of Strides Pharma Science, attributed these achievements to the company's focus on cost management and diligent execution.

Looking ahead, the company intends to bolster its R&D efforts to drive sustainable long-term growth. Consequently, Strides Pharma shares saw a 4.71% rise, trading at Rs 965.95 apiece on the BSE.

(With inputs from agencies.)